Moderna submitted regulatory applications for its mRNA seasonal influenza vaccine, mRNA-1010, to agencies in the U.S., Europe, Canada and Australia, seeking approval for use in people aged 50 and older. Company trial data cited a 27% reduction in influenza illness compared with marketed vaccines in the studied age group; Moderna positioned the shot as part of a respiratory vaccine franchise intended to stabilize revenues and support broader R&D investments. Moderna framed the filings as a step toward geographic expansion and revenue diversification following prior COVID-19 and RSV programs. Regulators will weigh efficacy relative to existing flu vaccines and the mRNA platform's manufacturing and safety data as part of standard review processes.